10 recruiting. 10 Phase 3, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 10 | Recruiting 10 |
| Phase 2 | 3 | Recruiting 3 |
Follow Skin Abnormalities: new trials by email Literature Review of Skin Abnormalities trials Research Report on Skin Abnormalities
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety Study to Evaluate SD-101 in Epidermolysis Bullosa SD-101 Dermal Cream (6%), Vehicle (SD-101 0%) - Epidermolysis Bullosa (EB) | Phase 3 | Recruiting | Paradigm Therapeutics | 80 | 2026-07-21 | 2026-10-15 |
| Phase 2/3 Clinical Study of QRX003 Lotion in Subjects With Netherton Syndrome QRX003 - Netherton Syndrome | Phase 2 / Phase 3 | Recruiting | Quoin Pharmaceuticals | 16 | 2026-03-19 | 2026-09-28 |
| Saccharomyces Boulardii CNCM I-745 in Irritable Bowel Syndrome Saccharomyces Boulardii 250 MG, Placebo 250 mg - IBS (Irritable Bowel Syndrome), IBS-D (Diarrhea-predominant) | Phase 3 | Recruiting | Biocodex | 406 | 2025-10-22 | 2025-11-18 |
| Clinical Study of QRX003 Lotion in Subjects With Netherton Syndrome QRX003, 4% Lotion - Netherton Syndrome | Phase 2 / Phase 3 | Recruiting | Quoin Pharmaceuticals | 8 | 2025-10-06 | 2026-08-31 |
| A Study Comparing KB803 and Matched Placebo in Patients With Dystrophic Epidermolysis Bullosa KB803, Placebo - Dystrophic Epidermolysis Bullosa, DEB - Dystrophic Epidermolysis Bullosa | Phase 3 | Recruiting | Krystal Biotech, Inc. | 16 | 2025-06-20 | 2026-03-12 |
| A Study to Learn About the Safety and Efficacy of the Drug Oleogel-S10 in Japanese Patients With Epidermolysis Bullosa Oleogel-S10 - Epidermolysis Bullosa, Junctional Epidermolysis Bullosa | Phase 3 | Recruiting | Chiesi Farmaceutici S.p.A. | 6 | 2025-04-18 | 2025-12-22 |
| The Prevention of Systemic Ectopic Mineralization in Pseudoxanthoma Elasticum Etidronate, Placebo - Pseudoxanthoma Elasticum | Phase 3 | Recruiting | UMC Utrecht | 76 | 2023-04-26 | 2023-04-27 |
| Open Label, Safety and Efficacy Study of QRX003 Lotion in Subjects With Netherton Syndrome QRX003, 4% Lotion - Netherton Syndrome | Phase 2 / Phase 3 | Recruiting | Quoin Pharmaceuticals | 20 | 2023-03-14 | 2026-08-31 |
| A Study Evaluating the Safety and Pharmacokinetics of QTORIN Rapamycin 3.9% Anhydrous Gel in the Treatment of Adults With Pachyonychia Congenita PTX-022 - Pachyonychia Congenita | Phase 3 | Recruiting | Palvella Therapeutics, Inc. | 45 | 2022-11-15 | 2022-12-09 |
| Clinical Trial to Compare the Efficacy of Celiprolol to Placebo in Patients With Vascular Ehlers-Danlos Syndrome ACER-002 (celiprolol) 200 mg BID, Placebo BID - Vascular Ehlers-Danlos Syndrome | Phase 3 | Recruiting | Acer Therapeutics Inc. | 150 | 2022-11-07 | 2025-08-24 |
Netherton Syndrome (3) · Epidermolysis Bullosa (2) · Epidermolysis Bullosa Dystrophica (2) · Collagen Diseases (1) · Congenital Abnormalities (1) · Connective Tissue Diseases (1) · Corneal Injuries (1) · Ehlers-Danlos Syndrome, Type IV (1) · Epidermolysis Bullosa, Junctional (1) · Genetic Diseases, Inborn (1) · Ichthyosis Bullosa of Siemens (1) · Irritable Bowel Syndrome (1) · Pachyonychia Congenita (1) · Pruritus (1) · Pseudoxanthoma Elasticum (1)
Congenital, Hereditary, and Neonatal Diseases and Abnormalities (10) · Skin Diseases, Genetic (10) · Skin and Connective Tissue Diseases (10) · Congenital Abnormalities (9) · Genetic Diseases, Inborn (9) · Skin Diseases (9) · Abnormalities, Multiple (4) · Ichthyosis (4) · Infant, Newborn, Diseases (4) · Keratosis (4) · Connective Tissue Diseases (3) · Ichthyosiform Erythroderma, Congenital (3) · Skin Diseases, Vesiculobullous (3) · Cardiovascular Diseases (2)
BID protein, human (1) · Celiprolol (1) · Etidronic Acid (1)
Quoin Pharmaceuticals (3) · Acer Therapeutics Inc. (1) · Biocodex (1) · Chiesi Farmaceutici S.p.A. (1) · Krystal Biotech, Inc. (1) · Palvella Therapeutics, Inc. (1) · Paradigm Therapeutics (1) · UMC Utrecht (1)
United States (7) · Japan (1) · Netherlands (1) · Portugal (1) · Spain (1) · United Kingdom (1)
Oana Bernard, DR (1) · Tony Andrasfay (1)